New biomarker for prediction of response to irinotecan treatment in colorectal cancer patients

Developed by: Fundació Hospital Universitari Vall d’Hebron - Institut de Recerca


The identified biomarker is involved in the mechanism that is inhibited by irinotecan. Therefore, a tumor with high biomarker levels is able to revert irinotecan effects, inducing resistance to this drug. This biomarker can be used to identify patients with low probability of response to an  irinotecan-based treatment, so they should receive treatment with alternative drugs. This will allow a doctor to decide earlier the feasibility of this treatment and to increase the survival rate of patients.

Stage of development: TRL 4, Validated in the laboratory.


IP: Patent rights up to 2029. National phase in EU. Patent granted in USA.

Health technology: